Andrea Sartore-Bianchi Selected Research

entrectinib

11/2023	Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report.
10/2022	Application of histology-agnostic treatments in metastatic colorectal cancer.
1/2020	Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
1/2017	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
1/2016	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
12/2015	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrea Sartore-Bianchi Research Topics

Disease

100	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 05/2005
78	Neoplasms (Cancer) 02/2024 - 04/2005
12	Disease Progression 11/2023 - 06/2012
11	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2012
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2023 - 01/2017
5	Circulating Neoplastic Cells 05/2021 - 02/2014
4	Microsatellite Instability 01/2021 - 01/2019
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 05/2004
3	Adenocarcinoma 03/2023 - 01/2021
3	Stomach Neoplasms (Stomach Cancer) 01/2023 - 11/2019
3	Carcinoma (Carcinomatosis) 11/2021 - 04/2005
3	Malignant Mesothelioma 10/2007 - 11/2002
2	Carcinogenesis 01/2024 - 03/2014
2	Exanthema (Rash) 11/2022 - 06/2016
2	Anemia 11/2022 - 04/2005
2	Rectal Neoplasms (Rectal Cancer) 01/2020 - 09/2019
2	Colonic Neoplasms (Colon Cancer) 01/2019 - 10/2013
1	Vomiting 06/2023
1	Nausea 06/2023
1	Intestinal Perforation 01/2023
1	Hand-Foot Syndrome 01/2023
1	Asthenia 01/2023
1	Heart Arrest (Cardiac Arrest) 01/2023
1	Hypertension (High Blood Pressure) 01/2023
1	Turcot syndrome 01/2022
1	Bites and Stings (Sting) 05/2021
1	Myasthenia Gravis 02/2021

Drug/Important Bio-Agent (IBA)

26	ErbB Receptors (EGF Receptor)IBA 04/2024 - 05/2005
25	Panitumumab (Vectibix)FDA Link 11/2022 - 05/2005
24	Cetuximab (Erbitux)FDA Link 11/2021 - 05/2005
20	Monoclonal AntibodiesIBA 01/2023 - 05/2005
19	Biomarkers (Surrogate Marker)IBA 02/2024 - 10/2009
13	Circulating Tumor DNAIBA 04/2024 - 02/2014
13	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2023 - 05/2004
10	Proteins (Proteins, Gene)FDA Link 02/2024 - 12/2014
7	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 01/2018
7	Immune Checkpoint InhibitorsIBA 07/2023 - 01/2019
7	regorafenibIBA 01/2023 - 05/2013
7	AntibodiesIBA 01/2022 - 08/2010
6	entrectinibIBA 11/2023 - 12/2015
6	Calcibiotic Root Canal SealerIBA 01/2023 - 02/2014
6	Lapatinib (GW572016)FDA Link 01/2021 - 11/2015
6	Trastuzumab (Herceptin)FDA Link 01/2021 - 11/2015
5	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 12/2016
5	Phosphotransferases (Kinase)IBA 01/2017 - 06/2013
4	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 01/2017
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2024 - 12/2016
3	pertuzumabIBA 01/2021 - 01/2020
3	Cell-Free Nucleic AcidsIBA 01/2021 - 07/2017
3	Leucovorin (Folinic Acid)FDA Link 01/2020 - 09/2019
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 01/2020
2	trifluridine tipiracil drug combinationIBA 01/2023 - 01/2019
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2023 - 02/2016
2	olaparibIBA 01/2023 - 01/2020
2	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2019
2	pembrolizumabIBA 10/2022 - 01/2022
2	VaccinesIBA 01/2022 - 01/2022
2	Anaplastic Lymphoma KinaseIBA 01/2022 - 12/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 04/2005
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2020
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2020
2	trastuzumab deruxtecanIBA 01/2021 - 01/2020
2	Capecitabine (Xeloda)FDA Link 01/2020 - 10/2013
2	Dacarbazine (DIC)FDA LinkGeneric 01/2017 - 04/2013
2	Codon (Codons)IBA 06/2016 - 10/2010
2	Growth Factor ReceptorsIBA 03/2014 - 05/2005
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2014 - 06/2012
2	MMEIBA 10/2007 - 11/2002
2	Interleukin-2 (IL2)IBA 10/2004 - 11/2002
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 02/2024
1	MutagensIBA 01/2024
1	colibactinIBA 01/2024
1	CrizotinibIBA 11/2023
1	PlatinumIBA 03/2023
1	HMPL-013IBA 01/2023
1	larotrectinibIBA 10/2022
1	dostarlimabIBA 10/2022
1	disitamab vedotinIBA 03/2022
1	trastuzumab duocarmazineIBA 03/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	mRNA VaccinesIBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	avelumabIBA 11/2021
1	InterferonsIBA 05/2021
1	SteroidsIBA 02/2021
1	Cisplatin (Platino)FDA LinkGeneric 02/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2021
1	Pyridostigmine Bromide (Pyridostigmine)FDA LinkGeneric 02/2021

Therapy/Procedure

60	Therapeutics 01/2023 - 06/2005
15	Drug Therapy (Chemotherapy) 01/2023 - 05/2005
6	Immunotherapy 01/2023 - 05/2004
5	Retreatment 11/2023 - 02/2019
4	Precision Medicine 01/2021 - 11/2011
2	Radiotherapy 03/2023 - 02/2021
1	Combined Modality Therapy 03/2023
1	Hepatectomy 01/2023
1	Contraindications 02/2021
1	Critical Care (Surgical Intensive Care) 02/2021
1	Plasma Exchange 02/2021